Real-world effectiveness and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes and renal impairment: a subgroup analysis of the ATOS study

被引：0
|
作者：
Tirosh, A. [1 ,2 ]
Khan, N. [3 ]
Vargas-Uricoechea, H.
Mabunay, M. A. N. [4 ]
Coudert, M. [5 ]
Pilorget, V. [5 ]
Galstyan, G. [6 ]
机构：
[1] Chaim Sheba Med Ctr, Div Endocrinol Diabet & Metab, Tel Hashomer, Israel
[2] Tel Aviv Univ, Tel Hashomer, Israel
[3] Imperial Coll London, Diabet Ctr, Al Ain, U Arab Emirates
[4] Univ Cauca, Div Endocrinol & Metab, Dept Internal Med, Popayan Cauca, Colombia
[5] Sanofi, Singapore, Singapore
[6] Hlth Care Minist Russian Federat, Endocrinol Res Ctr, Moscow, Russia
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
506
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [31] The effectiveness of insulin glargine 300 U/ml among type 2 diabetes patients: analysis of a real world data
    Cohen, C. Melzer
    Shalev, V.
    Chodick, G.
    DIABETOLOGIA, 2019, 62 : S436 - S437
  • [32] Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study
    Hassanein, Mohamed
    Buyukbese, Mehmet Akif
    Malek, Rachid
    Pilorget, Valerie
    Naqvi, Mubarak
    Berthou, Baptiste
    Shaltout, Inass
    Sahay, Rakesh Kumar
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 166
  • [33] Comparative effectiveness of insulin glargine 300 U/mL and insulin degludec 100 U/mL in insulin naive type 2 diabetes adults: the Restore-2 naive cohort
    Fadini, G. P.
    Buzzetti, R.
    Larosa, M.
    Rossi, M. C.
    Nicolucci, A.
    Cucinotta, D.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 74 - 74
  • [34] Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Wardecki, M.
    Goyeau, H.
    Home, P. D.
    DIABETES & METABOLISM, 2017, 43 (04) : 351 - 358
  • [35] Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    Cetinarslan, Berrin
    Cetinkalp, Sevki
    Kaya, Ahmet
    Ersoy, Canan
    Kebapci, Nur
    Comlekci, Abdurrahman
    Tutuncu, Neslihan Bascil
    Deyneli, Oguzhan
    Oguz, Aytekin
    Ilkova, Hasan
    Yilmaz, Temel
    Hekimsoy, Zeliha
    Unubol, Mustafa
    Balci, Mustafa Kemal
    Atmaca, Ayseguel
    Dagdelen, Selcuk
    Yetkin, Ilhan
    Guler, Serdar
    Otunc, Goektuerk
    Ozhan, Leyla
    ENDOCRINOLOGY RESEARCH AND PRACTICE, 2024, 28 (01): : 4 - 11
  • [36] New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    DIABETIC MEDICINE, 2015, 32 : 78 - 78
  • [37] Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study
    Chen, Liming
    Wen, Binhong
    Liu, Haixia
    Wu, Hongmei
    Duan, Binhong
    Shu, Hongyan
    Zhang, Qiu
    Wu, Xiaohong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4571 - 4582
  • [38] Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
    Peter Wiesli
    Marcus Schories
    Diabetes Therapy, 2018, 9 : 2325 - 2334
  • [39] Lower hypoglycaemia rates with insulin glargine 300 U/ml vs insulin degludec 100 U/ml in insulin-naive adults with type 2 diabetes: the BRIGHT randomised trial
    Bolli, G. B.
    Cheng, A.
    Bosnyak, Z.
    Boelle-Le Corfec, E.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Rosenstock, J.
    DIABETOLOGIA, 2018, 61 : S442 - S442
  • [40] Real-world outcomes in people with type 2 diabetes (PWD2) and renal impairment receiving insulin glargine 300 U/mL (Gla-300) and insulin degludec 100U/mL or 200U/mL (IDeg): the DELIVER-R study
    Bailey, Timothy
    Urquhart, Scott
    Westerbacka, Jukka
    Gill, Jasvinder
    Nicholls, Charlie
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 128 : S59 - S59
12345